| Identification | Back Directory | [Name]
Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy- | [CAS]
2759855-37-1 | [Synonyms]
HDAC1/MAO-B-IN-1
Benzamide, 4-[[[(3-chlorophenyl)methyl]-2-propyn-1-ylamino]methyl]-N-hydroxy- | [Molecular Formula]
C18H17ClN2O2 | [MOL File]
2759855-37-1.mol | [Molecular Weight]
328.8 |
| Hazard Information | Back Directory | [Uses]
HDAC1/MAO-B-IN-1 is a potent, selective and cross the blood-brain barrier HDAC1/MAO-B inhibitor with IC50 values of 21.4 nM and 99.0 nM for HDAC1 and MAO-B, respectively. HDAC1/MAO-B-IN-1 has the potential for the research of Alzheimer’s disease[1]. | [in vivo]
HDAC1/MAO-B-IN-1 (20 mg/kg; i.g.) exhibits favorable BBB (blood–brain barrier) permeability[1].
HDAC1/MAO-B-IN-1 (15 mg/kg; i.p.) improves the learning and memory abilities of the ICR mice[1]. | Animal Model: | 6-8 weeks, ICR male mice[1] | | Dosage: | 20 mg/kg | | Administration: | I.g. | | Result: | Exhibited favorable BBB (blood–brain barrier) permeability. |
| Animal Model: | 20-25 g, ICR female mice[1] | | Dosage: | 15 mg/kg | | Administration: | I.p.; 15 consecutive days | | Result: | Improved the learning and memory abilities of the ICR mice. |
| [IC 50]
HDAC1: 21.4 nM (IC50); MAO-B: 99.0 nM (IC50) | [References]
[1] Yao C, et al. HDAC1/MAO-B dual inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids. Bioorg Chem. 2022; 122:105724. DOI:10.1016/j.bioorg.2022.105724 |
|
|